Characterization of plasma brain natriuretic peptide level in patients with type 2 diabetes

Endocrine Journal

Volumn 52, Issue 3, 2005, Pages 353-362

  Igarashi, Masahiko ^a   Jimbu, Yumi ^a   Hirata, Akihiko ^a   Tominaga, Makoto ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

BNP; Coronary heart disease; Diabetes mellitus; Diabetic complications

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; VASCULAR DISEASE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN;

EID: 22344446276     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.52.353     Document Type: Article

References (35)

1. Sudoh T, Kangawa K, Minamino N, Matsuo H (1998) A new natriuretic peptide in porcine brain. Nature 33: 278-281.
2. Minamino N, Aburaya M, Ueda S, Kangawa K, Matsuo H (1988) The presence of brain natriuretic peptide of 12,000 daltons in porcine heart. Biochem Biophys Res Commun 155: 740-746.
3. Saito Y, Nakao K, Itoh H, Yamada T, Mukoyama M, Arai H, Hosoda K, Shirakami G, Suga S, Minamino N (1989) Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 158: 360-368.
4. Ogawa Y, Nakao K, Mukoyama M, Shirakami G, Itoh H, Hosoda K, Saito Y, Arai H, Suga S, Jougasaki M (1990) Rat brain natriuretic peptide-tissue distribution and molecular form. Endocrinology 126: 2225-2227.
5. Nakao K, Ogawa Y, Suga S, Imura H (1992) Molecular biology and biochemistry of the natriuretic peptide system: 1. Natriuretic peptides. J Hypertens 10: 907-912.
6. Honda K, Nakao K, Mukoyama M, Saito Y, Jougasaki M, Shirakami G (1991) Expression of brain natriuretic peptide gene in human heart: Production in the ventricle. Hypertension 17: 1152-1155.
7. Kohno M, Horio T, Yokokawa K (1992) Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 92: 29-34.
8. Yandle T, Richards A, Gilbert A, Fisher S, Holmes S, Espiner E (1993) Assay of brain natriuretic peptide (BNP) in human plasma: Evidence for high-molecular-weight BNP as a major component in heart failure. J Clin Endocrinol Metab 76: 832-838.
9. Omland T, Aakvaag A, Bonarjee W, Caidahl K, Lie RT, Nilsen DW, Sundsfjord JA, Dickstein K (1996) Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: Comparison with plasma atrial natriuretic peptide and N-terminal pro-atrial natriuretic peptide. Circulation 93: 1963-1969.
10. Christoffersen C, Goetze JP, Bartels ED, Larsen MO, Ribel U, Rehfeld JF, Rolin B, Nielsen LB (2002) Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart. Hypertension 40: 54-60.
11. Inoue M, Kanda T, Arai M, Suga T, Suzuki T, Kobayashi I, Nagai R (1998) Impaired expression of brain natriuretic peptide gene in diabetic rats with myocardial infarction. Exp Clin Endocrinol Diabetes 106: 484-488.
12. Yano Y, Katsuki A, Gabazza EC, Ito K, Fujii M, Furuta M, Tuchihashi K, Goto H, Takatani K, Hori Y, Sumida Y, Adachi Y (1999) Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J Clin Endocrinol Metab 84: 2353-2356.
13. McKenna K, Smith D, Moore K, Glen A, Tormey W, Thompson CJ (2001) Brain natriuretic peptide increases urinary albumin and alpha-1 microglobulin excretion in Type 1 diabetes. Diabet Med 18: 973-978.
14. Isotani H, Kaneoka K, Sasaki I, Hida H, Kakutani S, Tasaki T (2000) Plasma brain natriuretic peptide levels in normotensive Type 2 diabetic patients without cardiac disease. Diabetes Care 23: 859-860.
15. Asakawa H, Fukui T, Tokunaga K, Kawakami F (2002) Plasma brain natriuretic peptide levels in normotensive Type 2 diabetic patients without cardiac disease and macroalbuminuria. J Diabetes Complications 16: 209-213.
16. American Diabetes Association (1998) Consensus development conference on the diagnosis of coronary heart disease in people with diabetes (Consensus Statement). Diabetes Care 21: 1551-1559.
17. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986.
18. American Diabetes Association (2002) Diabetic nephropathy. Diabetes Care 25 (Suppl 1): S85-S98.
19. Clerico A, Iervasi G, Mariani G (1999) Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in human. Horm Metab Res 31: 478-498.
20. Haffner SM, Lehto S, Rønnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234.
21. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V (1999) AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 34: 1348-1359.
22. Haffner SM (2000) Coronary heart disease in patients with diabetes. N Engl J Med 342: 1040-1042.
23. Shindler DM, Kostis JB, Yusuf S, Quinonose MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC (1996) Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77: 1017-1020.
24. Tenenbaum A, Morto M, Fisman EZ, Leor J, Freimark D, Boyko V, Mandelweig L, Adler Y, Sherer Y, Behar S (2003) Functional class in patients with heart failure is associated with the development of diabetes. Am J Med 114: 271-275.
25. Sayama H, Nakamura Y, Saito N, Kinoshita M (1999) Why is the concentration of plasma brain natriuretic peptide in elderly patients greater than normal? Coron Artery Dis 10: 537-540.
26. Inoue K, Sano H (2000) Troglitazone-induced pulmonary edema. Arch Intern Med 160: 871-872.
27. Benbow A, Stewart M, Yeoman G (2001) Thiazolidinediones for Type 2 diabetes: All glitazones may exacerbate heart failure. BMJ 322: 236.
28. Tang WH, Francis GS, Hoogwerf BJ, Young JB (2003) Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 41: 1394-1398.
29. Packer M, Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitors, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100: 2312-2318.
30. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587.
31. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators (2001) Effect of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 345: 861-869.
32. ALLHAT Collbotative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazocin vs. chlorthalidone: The anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283: 1967-1975.
33. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100: 1056-1064.
34. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN; Valsartan Heart Failure Trial Investigators (2002) Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation 106: 2454-2458.
35. Epshteyn V, Mudaliar S, Morrison K, Edelman S, Krishnaswamy P, Henry R, Kazanegra R, Maissel A, Clopton P (2003) Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 26: 2081-2087.